CDK2/TrkA-IN-1
CDK2/TrkA-IN-1 is a CDK2/TrkA inhibitor with IC50 values of 6.81 μM and 10.13 μM, respectively. CDK2/TrkA-IN-1 modulates cell cycle and cell proliferation signaling pathways and acts on EGFR and VEGFR-2 tyrosine kinases. CDK2/TrkA-IN-1 exhibits antiproliferative activity against MCF‑7, HCT‑116, and A‑549 tumor cells, with low toxicity to normal human lung fibroblasts. CDK2/TrkA-IN-1 induces cell cycle arrest and apoptosis in tumor cells. CDK2/TrkA-IN-1 can be used for research on breast cancer, colon cancer, and lung cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C15H13ClF3N3S
- Peso molecular:359.80
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas EGFR
MoreVer todos los productos específicos de isoformas VEGFR
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
CDK2 6.81 μM (IC50) |
TrkA 10.13 μM (IC50) |
VEGFR2 |
EGFR |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
0.05 μM
|
Antiproliferative activity against human MCF-7 breast cancer cells assessed as viability reduction by MTT assay with IC50 derived from dose-response curves.
Antiproliferative activity against human MCF-7 breast cancer cells assessed as viability reduction by MTT assay with IC50 derived from dose-response curves.
|
42800165 |
| HCT-116 | IC50 |
0.02 μM
|
Antiproliferative activity against human HCT-116 colon cancer cells assessed as viability reduction by MTT assay with IC50 derived from dose-response curves.
Antiproliferative activity against human HCT-116 colon cancer cells assessed as viability reduction by MTT assay with IC50 derived from dose-response curves.
|
42800165 |
| A549 | IC50 |
0.04 μM
|
Antiproliferative activity against human A-549 lung cancer cells assessed as viability reduction by MTT assay with IC50 derived from dose-response curves.
Antiproliferative activity against human A-549 lung cancer cells assessed as viability reduction by MTT assay with IC50 derived from dose-response curves.
|
42800165 |
| WI-38 | IC50 |
27.65 μM
|
Antiproliferative activity against normal human WI-38 lung fibroblast cells assessed as viability reduction.
Antiproliferative activity against normal human WI-38 lung fibroblast cells assessed as viability reduction.
|
42800165 |
In Vitro
CDK2/TrkA-IN-1 has IC50 values of 0.05, 0.02, and 0.04 µM against MCF-7, HCT-116, and A-549, respectively; its IC50 in WI-38 normal human lung fibroblasts is 27.65 µM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
- Annexin V plus membrane-impermeant dye apoptosis staining
- BrdU Incorporation Assay
- Somatic Cell Culture
- CFSE Dye Dilution Proliferation Assay
- Dye-dilution cell tracking and proliferation staining
- Protocol for Cell Cycle
- CCK-8/WST-8 Cell Proliferation Assay
- Cell Counting-Based Growth Curve Assay
- Colony Formation (Clonogenic) Assay
- Breast Cancer Modeling
- Cell Viability Determination by MTT Colorimetric Assay
- EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
- Ki-67 Immunostaining Proliferation Assay
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Flow cytometric DNA-content cell-cycle staining
- PCNA Immunodetection Proliferation Assay
- Protocol for Cell Counting and Cell Density Analysis
- Apoptosis Solutions
- MTT Cell Proliferation Assay
Chemical Information
-
Peso molecular 359.80
-
Fòrmula C15H13ClF3N3S
-
SMILES
C=CCNC1=NC(SCC2=CC=C(Cl)C=C2)=NC(C(F)(F)F)=C1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)